Indivisible Partners Acquires Shares of 10,395 Bristol Myers Squibb Company $BMY

Indivisible Partners acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,395 shares of the biopharmaceutical company’s stock, valued at approximately $560,000.

A number of other large investors also recently modified their holdings of BMY. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the 2nd quarter worth about $25,000. Physician Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the last quarter. EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth about $32,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Bristol Myers Squibb in the 3rd quarter worth about $35,000. Finally, Garner Asset Management Corp bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth about $35,000. 76.41% of the stock is currently owned by institutional investors.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Zacks (covered on Yahoo Finance) highlights BMY as a top value stock for long‑term investors, emphasizing attractive style scores and dividend appeal that support buy‑and‑hold interest. Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
• Positive Sentiment: BMY is named in reports about BioNTech expanding pivotal oncology trials done in collaboration with Bristol Myers Squibb—this pipeline activity can boost long‑term revenue potential if trials progress. BioNTech Expands Oncology Trials And Reshapes Manufacturing As Investors Weigh Upside
• Positive Sentiment: BMY will participate at the Bank of America Securities Healthcare Conference, giving management a forum to reinforce guidance, pipeline timelines and commercialization plans—an opportunity to reassure investors. Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
• Neutral Sentiment: BMY launched a nationwide “Won’t Lose” World Cup‑focused patient campaign to raise brand awareness; marketing may aid long‑term patient engagement but has limited immediate earnings impact. Bristol Myers Squibb World Cup Push Meets Valuation And Earnings Questions
• Neutral Sentiment: Analysts’ Q1 call questions (MSN recap) show market attention on growth drivers and margin dynamics—such scrutiny can amplify short‑term volatility even when fundamentals are intact. Bristol-Myers Squibb’s Q1 earnings call: Our top 5 analyst questions
• Neutral Sentiment: Commentary questioning whether BMY still offers value after a ~25% one‑year share gain highlights investor debate over valuation vs. yield; this may encourage profit taking. Is Bristol Myers Squibb (BMY) Offering Value After A 25.7% One Year Share Price Gain

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Morgan Stanley restated an “underweight” rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Cantor Fitzgerald raised their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 8th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Scotiabank restated a “sector perform” rating and issued a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Finally, Bank of America dropped their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Stock Down 0.7%

Bristol Myers Squibb stock opened at $56.18 on Friday. The stock has a market cap of $114.73 billion, a price-to-earnings ratio of 15.78, a PEG ratio of 0.16 and a beta of 0.26. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company’s 50-day moving average price is $59.28 and its two-hundred day moving average price is $54.91. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.29 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.5%. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.05% of the stock is owned by corporate insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.